The Effect of High Dose Salbutamol on Muscle Performance
NCT ID: NCT01415596
Last Updated: 2011-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2011-08-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salmeterol Effect on Exercise Performance
NCT06655012
Physiological Response to Salbutamol and Exercise
NCT03902106
Salbutamol, Pharmacogenetics and Breathing Mechanics
NCT01903785
cAMP Signaling and Muscle Adaptations
NCT02557581
Can Anti-asthmatic Medication Improve Sprint Performance in Healthy Endurance Athletes?
NCT04402658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Salbutamol
salbutamol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salbutamol
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18-45
* training frequency \> 10 hrs/wk
* informed consent
Exclusion Criteria
* chronic diseases, as well as asthma
* allergy to the study drugs
* intake of any form of medicin or inhibited drugs during the study
* use of beta2-agonist 14 days before the intervention
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bispebjerg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bispebjerg Hospital
Copenhagen Northwest, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SALMUS2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.